- ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
- Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
- ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
- ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
- ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
More ▼
Key statistics
On Friday, Immunitybio Inc (IBRX:NSQ) closed at 6.10, -42.07% below its 52-week high of 10.53, set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.00 |
---|---|
High | 6.36 |
Low | 5.91 |
Bid | 6.05 |
Offer | 6.16 |
Previous close | 6.09 |
Average volume | 3.10m |
---|---|
Shares outstanding | 691.57m |
Free float | 153.59m |
P/E (TTM) | -- |
Market cap | 4.44bn USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼